Literature DB >> 32727832

Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution.

Hanna Hakvoort1,2, Evelyn Bovenkamp1,2, Kerryl E Greenwood-Quaintance2, Suzannah M Schmidt-Malan2, Jay N Mandrekar3, Audrey N Schuetz2,4, Robin Patel5,4.   

Abstract

This study aimed to determine whether agar dilution, research-use-only disk diffusion (Mast Group Ltd., Bootle Merseyside, UK), Etest (bioMérieux, Inc., Durham, NC), and MIC test strip (MTS) (Liofilchem, Inc., Waltham, MA) methods yield equivalent results to those of broth microdilution (BMD) for imipenem-relebactam susceptibility testing using a collection of 297 Gram-negative bacilli, including members of the order Enterobacterales and Pseudomonas aeruginosa, enriched for drug resistance. MIC and disk diameter results were interpreted using United States Food and Drug Administration breakpoints. Overall, 76.8% of the isolates tested were susceptible to imipenem-relebactam by BMD. MIC values for agar dilution, Etest, and MTS were not significantly different from that for BMD, although they tended to be 1 to 2 dilutions higher. Essential agreement was 95.6% for agar dilution, 90.6% for Etest, and 85.2% for MTS. Categorical agreement was 98.0% for agar dilution, 73.1% for disk diffusion, 96.3% for Etest, and 96.6% for MTS. In conclusion, agar dilution and Etest yielded comparable results to BMD for imipenem-relebactam.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  agar dilution; broth microdilution; disk diffusion; gradient strips; imipenem-relebactam; susceptibility testing

Mesh:

Substances:

Year:  2020        PMID: 32727832      PMCID: PMC7512178          DOI: 10.1128/JCM.00695-20

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

Review 1.  β-lactam/β-lactamase inhibitor combinations: from then to now.

Authors:  Kimberly A Toussaint; Jason C Gallagher
Journal:  Ann Pharmacother       Date:  2014-10-31       Impact factor: 3.154

2.  Relative contribution of biological variation and technical variables to zone diameter variations of disc diffusion susceptibility testing.

Authors:  Michael Hombach; Carlos Ochoa; Florian P Maurer; Tamara Pfiffner; Erik C Böttger; Reinhard Furrer
Journal:  J Antimicrob Chemother       Date:  2015-10-12       Impact factor: 5.790

3.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

4.  In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Authors:  James A Karlowsky; Sibylle H Lob; Krystyna M Kazmierczak; Stephen P Hawser; Sophie Magnet; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

Review 5.  How to accelerate antimicrobial susceptibility testing.

Authors:  E A Idelevich; K Becker
Journal:  Clin Microbiol Infect       Date:  2019-05-02       Impact factor: 8.067

6.  Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI).

Authors:  Cornelius Remschmidt; Sandra Schneider; Elisabeth Meyer; Barbara Schroeren-Boersch; Petra Gastmeier; Frank Schwab
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

Review 7.  Clinical implications of antimicrobial resistance for therapy.

Authors:  Alasdair P Macgowan
Journal:  J Antimicrob Chemother       Date:  2008-11       Impact factor: 5.790

8.  Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  David M Livermore; Marina Warner; Shazad Mushtaq
Journal:  J Antimicrob Chemother       Date:  2013-05-21       Impact factor: 5.790

9.  Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.

Authors:  Balaji Veeraraghavan; Mark Ranjan Jesudason; John Antony Jude Prakasah; Shalini Anandan; Rani Diana Sahni; Agila Kumari Pragasam; Yamuna Devi Bakthavatchalam; Rajesh Joseph Selvakumar; T N Dhole; Camilla Rodrigues; Indranil Roy; Sangeetha Joshi; Bhaskar Narayan Chaudhuri; D S Chitnis
Journal:  Indian J Med Microbiol       Date:  2018 Jan-Mar       Impact factor: 0.985

10.  Antimicrobial susceptibility of gram-negative bacilli isolated from intra-abdominal and urinary-tract infections in Mexico from 2009 to 2015: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Alfredo Ponce-de-Leon; Eduardo Rodríguez-Noriega; Rayo Morfín-Otero; Dora P Cornejo-Juárez; Juan C Tinoco; Areli Martínez-Gamboa; Carmen J Gaona-Tapia; M Lourdes Guerrero-Almeida; Alexandra Martin-Onraët; José Luis Vallejo Cervantes; José Sifuentes-Osornio
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

View more
  3 in total

Review 1.  The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Authors:  Tanis C Dingle; Johann Pitout
Journal:  J Clin Microbiol       Date:  2022-04-07       Impact factor: 11.677

Review 2.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06

3.  Insights into the Antimicrobial Resistance Profile of a Next Generation Probiotic Akkermansia muciniphila DSM 22959.

Authors:  Daniela Machado; Joana Cristina Barbosa; Diana Almeida; José Carlos Andrade; Ana Cristina Freitas; Ana Maria Gomes
Journal:  Int J Environ Res Public Health       Date:  2022-07-27       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.